Instrument Inactif

Communiqués NPS Pharmaceuticals, Inc.

Actions

US62936P1030

Recherche biotechnologique et médicale

Cours en clôture Nasdaq
- ^USD	-

12/02/15	Shire : Hausse du résultat du T4, le titre monte	RE
26/01/15	American Airlines : Les valeurs à suivre sur les marchés américains	RE

Communiqués

21/02/15	NPS Pharmaceuticals : Shire Completes Acquisition of NPS Pharma	PR
06/02/15	NPS Pharmaceuticals : Biotech Stocks Review - Arena Pharma, Amgen, NPS Pharma, ZIOPHARM Oncology, and Advaxis	PR
24/01/15	NPS Pharmaceuticals : FDA Approves Natpara® (parathyroid hormone) for Injection as an Adjunct to Calcium and Vitamin D to Control Hypocalcemia in Patients with Hypoparathyroidism	BU
16/01/15	NPS Pharmaceuticals : NPSP INVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of NPS Pharmaceuticals Inc. in Connection with the Fairness of the Sale of the Company to Shire plc	BU
14/01/15	NPS Pharmaceuticals : NPSP INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation of the Board of Directors of NPS Pharmaceuticals Inc. Concerning the Fairness of the Sale of the Company to Shire plc	BU
13/01/15	NPS Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of NPS Pharmaceuticals, Inc.	PR
13/01/15	NPS Pharmaceuticals : Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of NPS Pharmaceuticals, Inc. Stockholders	BU
12/01/15	NPS Pharmaceuticals : PHARMA ALERT: Johnson & Weaver, LLP Investigates the Fairness of Price and Process in Proposed Sale of Pharmaceuticals, Inc. to Shire plc	BU
12/01/15	NPS Pharmaceuticals : Buyout Of NPS Pharmaceuticals, Inc. - National Securities Law Firm Seeks Higher Price For Shareholders. Encourages Shareholders To Contact Law Firm For More Information	PR
11/01/15	NPS Pharmaceuticals : PLShire to Acquire NPS Pharma as Further Step in Building a Leading Biotech	PR
05/01/15	NPS Pharmaceuticals : Pharma to Present at J.P. Morgan Healthcare Conference	BU
04/12/14	NPS Pharmaceuticals : Pharma to Present at Oppenheimer Healthcare Conference	BU
02/12/14	NPS Pharmaceuticals : European Medicines Agency Validates Marketing Authorization Application for Natpar® (parathyroid hormone (rDNA)) in Hypoparathyroidism	BU
25/11/14	NPS Pharmaceuticals : Pharma to Present at Deutsche Bank BioFEST Conference	BU
24/11/14	NPS Pharmaceuticals : Teduglutide Granted Orphan Drug Designation in Japan	BU
11/11/14	NPS Pharmaceuticals : Pharma to Present at Jefferies Global Healthcare Conference	BU
10/11/14	NPS Pharmaceuticals : Pharma Reports Third-Quarter 2014 Financial Results	BU
04/11/14	NPS Pharmaceuticals : Pharma Appoints Pierre Legault to Board of Directors	BU
03/11/14	NPS Pharmaceuticals : Pharma to Report Third Quarter 2014 Financial Results	BU
23/10/14	NPS Pharmaceuticals : PDUFA Action Date for Natpara® BLA Extended Three Months to January 24, 2015	BU
24/09/14	NPS Pharmaceuticals : Pharma : to Present at Leerink Partners Rare Disease Roundtable	BU
15/09/14	NPS Pharmaceuticals : New Product Launch, Accelerated Drug Approvals, Study Initiation, and Market Activity - Research Reports on Johnson & Johnson, Merck, Medtronic, Pharmacyclics and NPS Pharma	PR
12/09/14	NPS Pharmaceuticals : FDA Advisory Committee Recommends Approval of Natpara® for Long-Term Treatment of Hypoparathyroidism	BU
12/09/14	NPS Pharmaceuticals : Pharma Stock Trading Halted Today; FDA Advisory Committee to Review Natpara® Biologics License Application	BU
10/09/14	NPS Pharmaceuticals : FDA Posts Briefing Materials for Advisory Committee Meeting Reviewing Natpara® for Hypoparathyroidism	BU